These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 38936819)

  • 41. Reduction of L-DOPA-induced dyskinesia by the selective metabotropic glutamate receptor 5 antagonist 3-[(2-methyl-1,3-thiazol-4-yl)ethynyl]pyridine in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned macaque model of Parkinson's disease.
    Johnston TH; Fox SH; McIldowie MJ; Piggott MJ; Brotchie JM
    J Pharmacol Exp Ther; 2010 Jun; 333(3):865-73. PubMed ID: 20231306
    [TBL] [Abstract][Full Text] [Related]  

  • 42. L-DOPA-induced behavioral sensitization of motor activity in the MPTP-treated common marmoset as a Parkinson's disease model.
    Ando K; Inoue T; Itoh T
    Pharmacol Biochem Behav; 2014 Dec; 127():62-9. PubMed ID: 25449794
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Levetiracetam potentiates the antidyskinetic action of amantadine in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-lesioned primate model of Parkinson's disease.
    Hill MP; Ravenscroft P; Bezard E; Crossman AR; Brotchie JM; Michel A; Grimée R; Klitgaard H
    J Pharmacol Exp Ther; 2004 Jul; 310(1):386-94. PubMed ID: 15004218
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Changes in glutamate receptors in dyskinetic parkinsonian monkeys after unilateral subthalamotomy.
    Jourdain VA; Morin N; Grégoire L; Morissette M; Di Paolo T
    J Neurosurg; 2015 Dec; 123(6):1383-93. PubMed ID: 25932606
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Metabotropic Glutamate Receptor 4 (mGlu4) Positive Allosteric Modulators Lack Efficacy in Rat and Marmoset Models of L-DOPA-Induced Dyskinesia.
    Finlay CJ; Jackson MJ; Fisher R; Bundgaard C; Rose S; Duty S
    J Parkinsons Dis; 2024; 14(2):245-259. PubMed ID: 38427500
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Chronic treatment with MPEP, an mGlu5 receptor antagonist, normalizes basal ganglia glutamate neurotransmission in L-DOPA-treated parkinsonian monkeys.
    Morin N; Morissette M; Grégoire L; Gomez-Mancilla B; Gasparini F; Di Paolo T
    Neuropharmacology; 2013 Oct; 73():216-31. PubMed ID: 23756168
    [TBL] [Abstract][Full Text] [Related]  

  • 47. mGlu5, Dopamine D2 and Adenosine A2A Receptors in L-DOPA-induced Dyskinesias.
    Morin N; Morissette M; Grégoire L; Di Paolo T
    Curr Neuropharmacol; 2016; 14(5):481-93. PubMed ID: 26639458
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Regulation of cortical and striatal 5-HT1A receptors in the MPTP-lesioned macaque.
    Huot P; Johnston TH; Koprich JB; Winkelmolen L; Fox SH; Brotchie JM
    Neurobiol Aging; 2012 Jan; 33(1):207.e9-19. PubMed ID: 21051107
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Novel antiepileptic drug levetiracetam decreases dyskinesia elicited by L-dopa and ropinirole in the MPTP-lesioned marmoset.
    Hill MP; Bezard E; McGuire SG; Crossman AR; Brotchie JM; Michel A; Grimée R; Klitgaard H
    Mov Disord; 2003 Nov; 18(11):1301-5. PubMed ID: 14639671
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Autoradiographic labelling of metabotropic glutamate type 2/3 receptors in the hemi-parkinsonian rat brain.
    Kim E; Frouni I; Shaqfah J; Bédard D; Huot P
    J Chem Neuroanat; 2024 Jul; 138():102422. PubMed ID: 38657828
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Characterization of 3,4-methylenedioxymethamphetamine (MDMA) enantiomers in vitro and in the MPTP-lesioned primate: R-MDMA reduces severity of dyskinesia, whereas S-MDMA extends duration of ON-time.
    Huot P; Johnston TH; Lewis KD; Koprich JB; Reyes MG; Fox SH; Piggott MJ; Brotchie JM
    J Neurosci; 2011 May; 31(19):7190-8. PubMed ID: 21562283
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The selective 5-HT
    Fisher R; Hikima A; Morris R; Jackson MJ; Rose S; Varney MA; Depoortere R; Newman-Tancredi A
    Neuropharmacology; 2020 May; 167():107997. PubMed ID: 32057799
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Melatonin enhances L-DOPA therapeutic effects, helps to reduce its dose, and protects dopaminergic neurons in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced Parkinsonism in mice.
    Naskar A; Prabhakar V; Singh R; Dutta D; Mohanakumar KP
    J Pineal Res; 2015 Apr; 58(3):262-74. PubMed ID: 25626558
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The dopamine D(2) receptor partial agonist aplindore improves motor deficits in MPTP-treated common marmosets alone and combined with L-dopa.
    Jackson MJ; Andree TH; Hansard M; Hoffman DC; Hurtt MR; Kehne JH; Pitler TA; Smith LA; Stack G; Jenner P
    J Neural Transm (Vienna); 2010 Jan; 117(1):55-67. PubMed ID: 19809864
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Further characterisation of psychosis-like behaviours induced by L-DOPA in the MPTP-lesioned marmoset.
    Kwan C; Nuara SG; Gourdon JC; Huot P
    Naunyn Schmiedebergs Arch Pharmacol; 2021 Aug; 394(8):1685-1692. PubMed ID: 33963876
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The monoamine reuptake inhibitor BTS 74 398 fails to evoke established dyskinesia but does not synergise with levodopa in MPTP-treated primates.
    Hansard MJ; Smith LA; Jackson MJ; Cheetham SC; Jenner P
    Mov Disord; 2004 Jan; 19(1):15-21. PubMed ID: 14743355
    [TBL] [Abstract][Full Text] [Related]  

  • 57. RGFP109, a histone deacetylase inhibitor attenuates L-DOPA-induced dyskinesia in the MPTP-lesioned marmoset: a proof-of-concept study.
    Johnston TH; Huot P; Damude S; Fox SH; Jones SW; Rusche JR; Brotchie JM
    Parkinsonism Relat Disord; 2013 Feb; 19(2):260-4. PubMed ID: 22901956
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Activation of mGlu 2/3 receptors with the orthosteric agonist LY-404,039 alleviates dyskinesia in experimental parkinsonism.
    Kang W; Frouni I; Kwan C; Desbiens L; Hamadjida A; Huot P
    Behav Pharmacol; 2024 Jun; 35(4):185-192. PubMed ID: 38563661
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Striatal leucine-rich repeat kinase 2 mRNA is increased in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned common marmosets (Callithrix jacchus) with L-3, 4-dihydroxyphenylalanine methyl ester-induced dyskinesia.
    Hurley MJ; Patel PH; Jackson MJ; Smith LA; Rose S; Jenner P
    Eur J Neurosci; 2007 Jul; 26(1):171-7. PubMed ID: 17614947
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Use of catechol-O-methyltransferase inhibition to minimize L-3,4-dihydroxyphenylalanine-induced dyskinesia in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned macaque.
    Huot P; Johnston TH; Snoeren T; Koprich JB; Hill MP; Fox SH; Brotchie JM
    Eur J Neurosci; 2013 Mar; 37(5):831-8. PubMed ID: 23281915
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.